TABLE 3.
Renal function in 55 patients developing renal insufficiency at baseline and at repeat measurement
| Preparation | n | Mean ± SD | P | |
|---|---|---|---|---|
| Baseline creatinine, (μmol/L) | Oral NaP | 42 | 93.7±18.0 | NS |
| PEG | 13 | 83.8±16.0 | ||
| Repeat creatinine, (μmol/L) | Oral NaP | 42 | 106.1±22.0 | NS |
| PEG | 13 | 102.3±22.2 | ||
| Baseline creatinine clearance, (mL/min) | Oral NaP | 42 | 78.6±17.0 | NS |
| PEG | 13 | 87.2±21.0 | ||
| Repeat creatinine clearance, (mL/min) | Oral NaP | 42 | 66.2±17.2 | NS |
| PEG | 13 | 71.4±16.5 | ||
| Change in creatinine concentration, (μmol/L) | Oral NaP | 42 | 12.4±15.0 | NS |
| PEG | 13 | 18.5±17.4 | ||
| Change in creatinine clearance, (mL/min) | Oral NaP | 42 | –12.4±13.1 | NS |
| PEG | 13 | –15.8±14.4 |
No significant differences were found between oral sodium phosphate (NaP) and polyethylene glycol (PEG) groups with regard to their renal function both at baseline and at repeat measurement. NS Nonsignificant